JP MORGAN/CALL/ELI LILLY & CO/1280/0.01/19.12.25 | Market Closed - Börse Stuttgart 09:56:51 03/06/2024 BST | ||
| 0.45 EUR | +2.27% |
|
| Current month | +2.27% | ||
| 1 month | +66.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 0.45 | +2.27% |
| 31/05/24 | 0.44 | +4.76% |
| 30/05/24 | 0.42 | +2.44% |
| 29/05/24 | 0.41 | -4.65% |
| 28/05/24 | 0.43 | -2.27% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 09:56 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK6074 |
| ISIN | DE000JK60746 |
| Date issued | 10/04/2024 |
| Strike | 1,280 $ |
| Maturity | 19/12/2025 (564 Days) |
| Parity | 100 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.45 € |
|---|---|
| Lowest since issue | 0.27 € |
| Spread | 0.03 € |
| Spread % | 6.12% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.3
USD
Average target price
852.5
USD
Spread / Average Target
+2.56%
- Stock Market
- Warrants
- Warrant
